Sign In
Buy LLY
$1,185.71
-6.23 (-0.523%)
At Close: Aug 07, 2026
Eli Lilly's head of diabetes and obesity unit to retire
07:06am, Wednesday, 04'th Oct 2023
Eli Lilly and Co said on Wednesday that the head of its diabetes and obesity division, Mike Mason, will retire by the end of the year after more than three decades with the drugmaker.
Why Eli Lilly Stock Was Looking Sickly Today
06:33pm, Tuesday, 03'rd Oct 2023
The pharmaceutical giant signed a deal to acquire cancer therapy developer Biopharma Global. Its asset-to-be is a developer of precision cancer therapies.
Eli Lilly Buys POINT Biopharma to Boost Its Cancer-Fighting Therapies
12:00pm, Tuesday, 03'rd Oct 2023
Shares of POINT Biopharma Global (PNT) skyrocketed over 80% in early trading on Tuesday after Eli Lilly (LLY) agreed to buy the radiopharmaceutical firm for $1.4 billion to expand its cancer-fighting
Eli Lilly Stock Cools Despite Big Cancer Investment
10:43am, Tuesday, 03'rd Oct 2023
Eli Lilly And Co (NYSE: LLY ) stock is down 2.5% to trade at $525.97 at last check, after the pharma company announced the acquisition of Point Biopharma Global (PNT) for $1.4 billion in an all-ca
Eli Lilly Acquiring Cancer Therapy Developer For $1.4 Billion—A Nearly 90% Premium
10:21am, Tuesday, 03'rd Oct 2023
American pharmaceutical company Eli Lilly plans to acquire cancer therapy firm Point Biopharma Global, the companies announced Tuesday, an expansion that comes as manu
Point Biopharma shares storm ahead 84% after Eli Lily's $1.4bn bid
09:05am, Tuesday, 03'rd Oct 2023
Shares in Point Biopharma Global jumped 84% following the announcement that pharmaceutical giant Eli Lilly and Co (NYSE:LLY) will acquire the company for $1.4 billion (£1.03 billion). The acquisition
Lilly's (LLY) Eczema Candidate Lebrikizumab Faces FDA Rejection
09:01am, Tuesday, 03'rd Oct 2023
Lilly (LLY) gets a CRL for the eczema candidate, lebrikizumab, based on inspection findings at a third-party manufacturer.
Eli Lilly to Buy Point Biopharma for $1.4 Billion
07:34am, Tuesday, 03'rd Oct 2023
Eli Lilly will acquire radiopharmaceutical company Point Biopharma Global for $12.50 a share.
Eli Lilly to buy cancer-focused Point Biopharma for $1.4 billion
07:07am, Tuesday, 03'rd Oct 2023
Eli Lilly and Co will buy cancer therapy developer Point Biopharma Global for $1.4 billion, the companies said on Tuesday.
Point Biopharma Global's stock jumps more than 80% after Lilly merger deal
06:56am, Tuesday, 03'rd Oct 2023
Point Biopharma Global, Inc.'s PNT, +0.22% stock was up 83.4% in premarket trading on Tuesday after Eli Lilly & Co. LLY, +0.22% said it will pay $12.50 a share to acquire the Indianapolis-based cancer
Drugmakers sign on to negotiate Medicare prices under protest
01:02pm, Monday, 02'nd Oct 2023
All the drugmakers that make the 10 prescription medicines subject to the first-ever price negotiations for the U.S. Medicare health program, including Amgen and Novartis , said they signed on to part
Q4 Stock Predictions: 3 Pharma Stocks Ready to Roar Into 2024
11:32am, Monday, 02'nd Oct 2023
With a few exceptions, pharmaceutical stocks have underperformed the broader market this year. The S&P Pharmaceutical Index is down 3% year to date versus a 12% gain in the benchmark S&P 500.
Stable Giants: 3 Bigwig Biotech Stocks for Consistent Returns
11:28am, Monday, 02'nd Oct 2023
Biotech stocks have had a rough post-pandemic. In a year where the S&P500 is up more than 10% year to date, the biotech sector is still negative to flat.
Eli Lilly Gets FDA Letter About Eczema Drug Concerns. The Stock Shrugs.
08:05am, Monday, 02'nd Oct 2023
The pharmaceutical company says the letter cited no worries about the safety of its lebrikizumab skin treatment.
Eli Lilly gets FDA complete response letter for skin treatment after inspection of third-party facility
06:59am, Monday, 02'nd Oct 2023
Eli Lilly & Co. said Monday the U.S. Food and Drug Administration has issued a complete response letter for its lebrikizumab, a treatment for moderate-to-severe atopic dermatitis, after an inspection
